FBXW2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.00160002514116E-09 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.008320E-04 |
Normal-vs-Stage2 |
9.984700E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
6.304300E-03 |
Stage1-vs-Stage2 |
5.407200E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
9.346800E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
6.163000E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.28919999623045E-08 |
Normal-vs-AfricanAmerican |
3.241600E-01 |
Normal-vs-Asian |
1.081210E-01 |
Caucasian-vs-AfricanAmerican |
2.332600E-01 |
Caucasian-vs-Asian |
9.005800E-01 |
AfricanAmerican-vs-Asian |
5.083800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
6.42269999999723E-05 |
Normal-vs-Female |
1.73273999999335E-05 |
Male-vs-Female |
8.952000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
2.032500E-02 |
Normal-vs-Extreme_Weight |
1.91904999999881E-05 |
Normal-vs-Obese |
2.224300E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
5.613200E-01 |
Normal_Weight-vs-Obese |
1.099380E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
1.010580E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
8.078100E-02 |
Normal-vs-Age(41-60Yrs) |
8.46400000000802E-05 |
Normal-vs-Age(61-80Yrs) |
1.429060E-04 |
Normal-vs-Age(81-100Yrs) |
2.75849999997746E-06 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.481800E-02 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.203800E-02 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.219600E-02 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.455000E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.099400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.241000E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
7.158800E-01 |
Normal-vs-Grade 3 |
8.333000E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
6.754200E-01 |
Grade 2-vs-Grade 4 |
7.158800E-01 |
Grade 3-vs-Grade 4 |
8.333000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
9.89380000038231E-07 |
Normal-vs-N1 |
1.624360E-02 |
N0-vs-N1 |
6.620200E-01 |
|
|